Alpelisib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 645 publications

A Novel Patient-Derived Xenograft Model of Inflammatory Breast Cancer.

A Novel Patient-Derived Xenograft Model of Inflammatory Breast Cancer.

Journal: Research square

Published: June 04, 2026

(Phospho)proteomic Profiling Reveals Mutation-Specific Adaptive Signaling to PI3Kα Inhibition in PIK3CA Mutant Breast Epithelial Cells.

(Phospho)proteomic Profiling Reveals Mutation-Specific Adaptive Signaling to PI3Kα Inhibition in PIK3CA Mutant Breast Epithelial Cells.

Journal: Journal of proteome research

Published: May 28, 2026

A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancers.

A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancers.

Journal: Research square

Published: May 25, 2026

Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis.

Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 20, 2026

Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.

Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.

Journal: Journal of clinical medicine

Published: April 16, 2026

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.

Journal: Neoplasia (New York, N.Y.)

Published: April 01, 2026

Alpelisib in PIK3CA-Related Overgrowth Spectrum (PROS): A Systematic Review of Real-World Evidence in over 100 Patients.

Alpelisib in PIK3CA-Related Overgrowth Spectrum (PROS): A Systematic Review of Real-World Evidence in over 100 Patients.

Journal: Cells

Published: March 30, 2026

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 19, 2026

Screening-confirmation approach for urinary alpelisib by silver-nanorod enabled portable SERS platform and LC-MS validation.

Screening-confirmation approach for urinary alpelisib by silver-nanorod enabled portable SERS platform and LC-MS validation.

Journal: Analytical and bioanalytical chemistry

Published: March 12, 2026

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

Journal: International journal of molecular sciences

Published: March 12, 2026

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Journal: Biologics : targets & therapy

Published: March 10, 2026

Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.

Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.

Journal: Cancers

Published: February 27, 2026

Showing 1-12 of 645

Last Updated: 06/30/2026